Tirofiban is an antiplatelet agent used in acute coronary care settings; it provides anti-clotting support used in acute settings. It is considered relevant in helping manage the risk of thrombotic cardiovascular events and is applied in situations involving acute, high-risk cardiovascular events.

---

Managing Acute Coronary Syndromes (ACS)

This therapeutic domain focuses on managing high-risk conditions, primarily Non-ST-Elevation Acute Coronary Syndromes (NSTE-ACS). This category includes urgent presentations like unstable angina and heart attack types such as NSTEMI. The medication is applied to address symptoms related to acute thrombus formation during these acute episodes, which are associated with severe or recurrent chest discomfort at rest and signs of heart muscle injury. This action provides supportive therapeutic benefit and may assist with addressing symptoms related to physiological stress in the heart and is applied to help address symptoms associated with increased physiological strain.

“Agrastat is used in clinical settings that involve acute or unstable symptom patterns, helping to ease the overall symptom load.”

Support During Coronary Artery Procedures

Agrastat is widely used as an adjunctive antiplatelet therapy for adult patients undergoing Percutaneous Coronary Intervention (PCI). This includes procedures like stenting or balloon angioplasty. It is specifically applied during this time to provide additional support during the high-stress period of the procedure. This support supports the process of maintaining blood flow through the treated artery and is relevant when short-term symptomatic assistance is needed during the interventional phase.

Quick Fact: Relief for Acute Chest Discomfort

The medicine supports the management of acute symptoms that create noticeable physiological strain, helping patients cope more steadily with difficult episodes of cardiac discomfort.

Regulatory References

1. NIH DailyMed official labeling

Who Can and Cannot Use Agrastat — Official Regulatory Information

Agrastat (tirofiban) is indicated for use in adult patients presenting with non-ST elevation acute coronary syndrome (NSTE-ACS). Eligibility is defined by a strict set of contraindications that prohibit its use, primarily due to the associated risk of bleeding complications.

Contraindicated Populations

The medicine must not be used in patients with:

• Known hypersensitivity to Agrastat or a history of thrombocytopenia following prior exposure to any GP IIb/IIIa inhibitor.
• Active internal bleeding or a history of bleeding diathesis, or who have experienced major surgery or severe physical trauma within the last month.
• A history of stroke within 30 days or any history of haemorrhagic stroke.
• Known intracranial disease (e.g., neoplasm or aneurysm).
• Severe uncontrolled hypertension (malignant hypertension) or severe liver failure.

Use Restrictions and Special Consideration

• Renal Impairment: Patients with severe kidney failure (creatinine clearance CrCl < 30 mL/min) require a 50% reduction in the maintenance infusion dosage.
• Age: Use in the pediatric population (under 18 years) has not been established. No specific dosage adjustment is required for the elderly unless severe renal impairment is present.

These regulatory rules define the specific clinical and physiological states where the medication is restricted or prohibited due to safety concerns, most notably those that increase the risk of serious bleeding.

Interactions with other medicines and products

The interaction profile of Agrastat (tirofiban) is defined primarily by its function as an antiplatelet agent, resulting in specific pharmacodynamic and pharmacokinetic considerations documented in regulatory labeling.

Pharmacodynamic Interactions

Category	Official Interaction Statements
Antithrombotic Agents	Co-administration with Fibrinolytics, other Antiplatelet drugs, and Anticoagulants is documented to result in pharmacodynamic synergism, which increases the overall risk of bleeding.
Standard Co-therapy	The combination with Unfractionated Heparin and Acetylsalicylic acid (ASA) is formally noted to increase bleeding time and the risk of bleeding.
Specific Caution	Concomitant use with Enoxaparin (a type of LMWH) is associated with a higher frequency of cutaneous and oral bleeding events; the safety and efficacy of this particular combination are not established.

Pharmacokinetic and Administration Notes

The metabolism of tirofiban is limited, and no specific CYP-mediated or transporter-mediated drug-drug interactions are documented in the labeling. The primary clearance is renal, which influences exposure in certain populations.

Category	Official Restriction or Finding
Administration Restriction	Diazepam must not be administered through the same intravenous line as Agrastat due to documented technical incompatibility.
Population Effect on Exposure	Impaired renal function causes a reduction in plasma clearance of tirofiban, which increases the risk of bleeding. Elderly patients (>65 years) also exhibit a lower plasma clearance rate.

Agrastat (tirofiban) functions as a non-peptide reversible antagonist, selectively targeting the glycoprotein (GP) IIb/IIIa receptor complex, which is an integrin found on the surface of platelets. This receptor, also known as alphaIIbbeta3, constitutes the final common pathway for platelet aggregation. Tirofiban mimics the Arg-Gly-Asp sequence of natural ligands, competitively binding to the GP IIb/IIIa receptor.

This molecular interaction prevents the binding of fibrinogen, von Willebrand factor, and other adhesive proteins to the receptor site. By blocking this crucial extracellular binding, the drug inhibits the cross-linking of adjacent platelets, thereby preventing the formation of platelet aggregates. The downstream consequence at the systemic level is the modulation of the coagulation cascade by reducing the mechanical capacity for thrombus formation.

How Agrastat (Tirofiban) is Used: Official Administration Guidelines

Agrastat is an antiplatelet agent used exclusively in acute care settings, and its administration is strictly governed by standard clinical protocols to ensure proper use during critical cardiovascular events. Its deployment is always restricted to a hospital environment under the direct supervision of specialist physicians.

---

Administration and Dosage Regimens

Agrastat is supplied as a sterile solution for intravenous (IV) infusion only. It is administered in a precise, body-weight-based, two-stage process that typically lasts for a short duration, ranging from 12 to 48 hours, depending on the clinical scenario.

Usage Component	Official Guidelines
Route of Administration	Intravenous (IV) infusion only.
Dosing Schedule (US)	25 mcg/kg IV bolus over 5 minutes followed by 0.15 mcg/kg/min continuous infusion.
Dosing Schedule (EU)	0.4 mcg/kg/min initial infusion for 30 minutes followed by 0.1 mcg/kg/min continuous infusion.

---

Procedural and Population Requirements

Administration requires the use of a controlled IV infusion pump. The concentrate form of the drug must be diluted prior to use to achieve the proper concentration for infusion. A key component of the official use protocol is the concomitant administration of other agents, such as unfractionated heparin and oral antiplatelet therapy.

Clinical protocols specify dosage adjustments for specific patient populations. For patients with severe renal impairment (creatinine clearance le 60 mL/min), the maintenance infusion rate must be reduced by 50%. Official labeling currently does not recommend the use of Agrastat in pediatric patients, as safety and effectiveness have not been established in this group. The administration protocol is not dependent on food intake.

Evidence for Use in Acute Coronary Syndromes (ACS)

Research examined the use of Agrastat in adult patients presenting with Acute Coronary Syndromes (ACS), which includes urgent conditions like unstable angina and a type of heart attack called Non-ST-Elevation Myocardial Infarction (NSTEMI). Large-scale randomized controlled trials (RCTs) were designed to explore short-term outcomes related to systemic imbalance. Studies monitored the frequency of a combined measure called Major Adverse Cardiovascular Events (MACE) over defined time intervals, typically assessed up to 30 days after the acute event. Research also examined how these patterns compared when Agrastat was studied alongside other commonly used antiplatelet agents.

The frequency of all-cause mortality was observed in some studies to differ based on the dosing strategies used, and certainty remains low regarding the consistency of critical outcomes when various trial designs are compared.

Evidence for Use as Support During Coronary Procedures

Research explored whether Agrastat, when administered adjunctively, was associated with outcomes in adult patients undergoing Percutaneous Coronary Intervention (PCI). Studies monitored outcomes related to blood flow achievement (TIMI flow grade) and changes in cardiac biomarkers following the procedure. Findings indicate that outcomes differed based on when the drug was first administered (e.g., pre-hospital versus procedural).

However, comparative evidence is lacking regarding which specific administration strategies were most frequently associated with certain post-procedural outcomes when combining Agrastat with newer oral antiplatelet medications.

Long-Term Studies and Follow-up Duration / Uncertainty

The primary research focus has been on acute care. Therefore, follow-up durations were limited, with assessments typically occurring within 30 days. While some evidence contributes to understanding symptom patterns over intermediate intervals, long-term outcomes are not fully established, and certainty remains low regarding outcomes like overall survival over extended periods.

Data for certain high-risk groups or those with complex comorbid conditions remain insufficient, and the results apply only to the populations studied in the main clinical trials.

Common questions about Agrastat (FAQ)

---

Q: How soon after stopping the infusion does the drug's effect wear off?

According to official product information, the medicine’s anti-clotting effect is reversible. Once the Agrastat infusion is discontinued, platelet aggregation typically returns to near baseline levels within approximately four to eight hours.

---

Q: What are the common symptoms of a severe allergic reaction to Agrastat?

Regulatory documents mention that severe allergic reactions, including anaphylaxis, have been reported in patients. These reactions may be associated with symptoms such as chills, low-grade fever, and a potentially significant drop in platelet count.

---

Q: What should I be tested for (blood tests) while I am receiving Agrastat?

Official prescribing information recommends that certain blood values be monitored while receiving this medicine. This typically includes checking your platelet count, hemoglobin, and hematocrit levels. These tests are performed by healthcare providers and are repeated throughout the course of treatment.

---

Q: What is the official brand name of the generic medicine Tirofiban?

The active ingredient in this medication is tirofiban. Agrastat is the officially recognized brand name for this non-peptide reversible antiplatelet medicine, which is classified as a Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor.

How to Store and Dispose of Agrastat (Tirofiban)

Agrastat must be stored at controlled room temperature, specifically 25 C (77 F), with excursions permitted between 15 C and 30 C. It is crucial to not freeze the solution.

Storage and Handling

The product must be protected from light and kept in its original outer carton or foil overpouch. Before use, the solution must be visually inspected, and it should not be administered if discoloration or particulate matter is visible. Agrastat is for single use; any remaining solution must be discarded.

Stability and Child Safety

For prepared solutions, stability is maintained for 24 hours at 25 C when protected from light. This medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired product must not be disposed of via household waste or wastewater. Patients should consult a pharmacist for official guidance on proper disposal procedures to protect the environment.